Live: Alzheimer's Plaque for the Layperson

Live: Alzheimer's Plaque for the Layperson

Webinar: Two Sides of Abeta for the Layperson

JOIN US – Wednesday, January 25, 2012,
1:00 pm EST for a
Cure Alzheimer’s Fund sponsored Webinar:
Two Sides of Abeta for the Layperson

Register Now

Please join us for a webinar, Two Sides of Abeta for the Layperson, on Wednesday, January 25th starting at 1 pm. This free and live presentation will be conducted over the internet. Each guest will participate through his/her own computer and phone. The presentation moderated by David Shenk, author of the national bestseller The Forgetting, Alzheimer’s: Portrait of an Epidemic, will feature Dr. Rudy Tanzi, and Dr. Rob Moir.

These Alzheimer’s experts will look at Abeta and its implications in the work toward a cure for Alzheimer's disease. For the last 27 years, Abeta, a fatty protein that is created in the brain, has been identified as “residual junk” and the leading cause of Alzheimer’s disease. As a result, the majority of research efforts into the cause of Alzheimer’s have targeted Abeta as the enemy. But recent studies financed by Cure Alzheimer’s Fund have indicated that simply wiping out Abeta in the brain is not the solution. Join in as these Alzheimer’s experts weigh in on how their work with Abeta is making progress toward a cure.

This is a great opportunity to learn about cutting edge research from some of the best minds tackling this disease and the paradigm changing work going on at Cure Alzheimer's Fund. Please also invite your friends to join in the webinar.

Questions and answers from the webinar will be posted here shortly after the presentation on January 25.


Dr. Rudy Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at the Harvard Medical School and the Director of the Genetics and Aging Research Unit at Massachusetts General Hospital. He has been investigating neurodegenerative disease since 1980 when he participated in the pioneering study that led to the location of the Huntington disease gene. He has identified several Alzheimer’s disease genes, including the first Alzheimer’s gene, the beta-amyloid protein precursor (APP). His work in the Alzheimer’s Genome Project, which has identified other new Alzheimer’s genes, was recognized by TIME magazine as one of the top 10 medical breakthroughs of 2008. Dr. Tanzi is a world-renowned leader in the studies of Alzheimer’s disease genetics.

Dr. Robert Moir, Assistant Professor in Neurology, MGH Neurology Research and Harvard Medical School, obtained his PhD from the University of Melbourne in the laboratory of Professor Colin Masters, one of the pioneers and founders of the modern era of Alzheimer's disease research. He joined the research unit of Professor Rudolph Tanzi at Harvard Medical School and Massachusetts General Hospital in 1994 as a Postdoctoral fellow. He is now an assistant Professor with joint appointments at HMS and MGH and runs his own research laboratory located at the MIND research facility in Charlestown MA.

David Shenk is the award-winning and national-bestselling author of six books, including The Genius in All of Us ("deeply interesting and important" - New York Times), The Forgetting ("remarkable" - Los Angeles Times), Data Smog ("indispensable" - New York Times), and The Immortal Game ("superb" - Wall Street Journal). He is a popular lecturer, a short-film director, and a correspondent for TheAtlantic.com. He has contributed to National Geographic, Slate, The New York Times, The Wall Street Journal, Gourmet, Harper's, Spy, The New Yorker, NPR, and PBS. Shenk lives in Brooklyn.

Related Videos & Articles

Can Vegetarians Escape Alzheimer's?

Dr. Rudy Tanzi

VIDEO

Harvard neurologist Dr. Rudy Tanzi is one of the world’s best-known Alzheimer's researchers. Dr. Tanzi is also a vegetarian. See him explain why.

Read more »

72 Minutes of Good News on Dementia Research

Video for Live: Alzheimer's Plaque for the Layperson

VIDEO

Dr. Rudolph Tanzi is called by some, “The Grandfather of Alzheimer’s Research.” In this full-length video, he describes the dramatic progress he has witnessed from 1984 until today. See why his outlook is so optimistic.

Read more »

Prana's PBT2 Improved Cognition in 12 Week Trial

Prana Biotechnology logo

In just 12 weeks of clinical trials, PBT2 significantly increased dementia patients' cognitive performance. Read the reaction of world-class experts, including Harvard's Dr. Tanzi. Learn how it works in Alzheimer's and Huntington's and what's next for PBT2.

Read more »

Comments

User login

, after login or registration your account will be connected.